Dayno Jeffrey M.
Known title: Chief Medical OfficerCIK: 0001615993
Associated companies
Transaction History
| HRMY | ▲ Buy | Option Exercise | 13,000 | $0 | 1/25/2026 | View on chart |
| HRMY | ▼ Sell | Tax Withholding | 5,654 | $208K | 1/25/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 10,500 | $0 | 1/24/2026 | View on chart |
| HRMY | ▼ Sell | Tax Withholding | 4,785 | $176K | 1/24/2026 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 20,000 | $164K | 12/12/2025 | View on chart |
| HRMY | ▼ Sell | Open Market | 20,000 | $802K | 12/12/2025 | View on chart |
| HRMY | ▼ Sell | Open Market | 5,933 | $238K | 12/12/2025 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 10,500 | $0 | 1/24/2025 | View on chart |
| HRMY | ▼ Sell | Tax Withholding | 4,567 | $174K | 1/24/2025 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 19,293 | $159K | 1/21/2025 | View on chart |
| HRMY | ▼ Sell | Open Market | 19,293 | $774K | 1/21/2025 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 15,000 | $123K | 11/3/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 15,000 | $900K | 11/3/2022 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 15,000 | $123K | 11/1/2022 | View on chart |
| HRMY | ▼ Sell | Open Market | 15,000 | $827K | 11/1/2022 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 14,099 | $116K | 10/19/2021 | View on chart |
| HRMY | ▼ Sell | Open Market | 14,099 | $608K | 10/19/2021 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 4,101 | $34K | 10/19/2021 | View on chart |
| HRMY | ▼ Sell | Open Market | 4,101 | $180K | 10/19/2021 | View on chart |
| HRMY | ▲ Buy | Option Exercise | 1,800 | $15K | 10/6/2021 | View on chart |
| HRMY | ▼ Sell | Open Market | 1,800 | $72K | 10/6/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook
HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook. HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.